Effect of genetic polymorphisms on therapeutic response and clinical outcomes in pancreatic cancer patients treated with gemcitabine

Author： Woo Hye In   Kim Ka-Kyung   Choi Hangseok   Kim Seonwoo   Jang Kee-Taek   Yi Jun Ho   Park Young Suk   Park Joon Oh   Lee Soo-Youn  

Publisher： Future Medicine

ISSN： 1462-2416

Source： Pharmacogenomics, Vol.13, Iss.9, 2012-07, pp. : 1023-1035

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Related content

Rapid deaminator status is associated with poor clinical outcome in pancreatic cancer patients treated with a gemcitabine-based regimen

By Serdjebi Cindy   Seitz Jean-François   Ciccolini Joseph   Duluc Muriel   Norguet Emmanuelle   Fina Frédéric   Lacarelle Bruno   Ouafik L'Houcine   Dahan Laetitia  

Pharmacogenomics, Vol. 14, Iss. 9, 2013-07 ,pp. : 1047-1051

Future Medicine

Access to resources Recommend Favorite

Population Pharmacokinetics of Gemcitabine and Its Metabolite in Japanese Cancer Patients: Impact of Genetic Polymorphisms

By Sugiyama Emiko   Kaniwa Nahoko   Kim Su-Ryang  

Clinical Pharmacokinetics, Vol. 49, Iss. 8, 2010-08 ,pp. : 549-558

Adis International

Access to resources Recommend Favorite

Association between DNA-repair polymorphisms and survival in pancreatic cancer patients treated with combination chemotherapy

By Giovannetti Elisa   Pacetti Paola   Reni Michele   Leon Leticia G   Mambrini Andrea   Vasile Enrico   Ghidini Michele   Funel Niccola   Lucchesi Matteo   Cereda Stefano   Peters Godefridus J   Cantore Maurizio  

Pharmacogenomics, Vol. 12, Iss. 12, 2011-12 ,pp. : 1641-1652

Future Medicine

Access to resources Recommend Favorite

Meta-Analysis of Randomised Trials Comparing Gemcitabine-Based Doublets versus Gemcitabine Alone in Patients with Advanced and Metastatic Pancreatic Cancer

By Banu Eugeniu  

Drugs & Aging, Vol. 24, Iss. 10, 2007-01 ,pp. : 865-879

Adis International

Access to resources Recommend Favorite

Erlotinib + gemcitabine of no value in pancreatic cancer

By  

Inpharma, Vol. 1, Iss. 1610, 2007-01 ,pp. : 3-3

Adis International

Access to resources Recommend Favorite